Program
tralesinidase alfa
Also written as “AX 250” and “Tralesinidase alfa (TA)”.
Its studies are mostly in Mucopolysaccharidosis III, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Allievex | 31 open or running | phase 4since Aug 5, 2022 | Feb 27, 2016 | Oct 2027phase 4 · NCT05492799 |
| Spruce Biosciences | 11 open or running | phase 3since Apr 28, 2026 | Apr 28, 2026 | Aug 2033phase 3 · NCT07579910 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 27, 2016First study: phase 2 study in Mucopolysaccharidosis IIINew to AllievexAllievex · NCT02754076 · 23 enrolled · United States, Colombia, Germany and more
- Mar 30, 2018Phase 2 study in Mucopolysaccharidosis IIIAllievex · NCT03784287 · 20 enrolled · United States, Colombia, Germany and more
- Aug 5, 2022Phase 4 study in Mucopolysaccharidosis IIIAllievex · NCT05492799 · 15 planned · United States, Colombia, Germany and more
- Apr 28, 2026Spruce Biosciences’ first study: phase 3 study in Mucopolysaccharidosis IIINew to Spruce BiosciencesSpruce Biosciences · NCT07579910 · 14 planned
Ahead
- Oct 2027Primary completion: phase 4 study in Mucopolysaccharidosis IIIAllievex · NCT05492799
- Aug 2033Primary completion: phase 3 study in Mucopolysaccharidosis IIISpruce Biosciences · NCT07579910
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07579910Mucopolysaccharidosis III | 3 | Not yet recruiting | Spruce Biosciences | Aug 2033 | 14 |
| NCT05492799Mucopolysaccharidosis III · United States, Colombia, Germany and more | 4 | By invitation | Allievex | Oct 2027 | 15 |
| NCT03784287Mucopolysaccharidosis III · United States, Colombia, Germany and more | 2 | UNKNOWN | Allievex | Jan 2025 | 20 |
| NCT02754076Mucopolysaccharidosis III · United States, Colombia, Germany and more | 2 | Completed | Allievex | Jun 24, 2020 | 23 |
How it is read
Names in the registry
- “AX 250”, 3 entries
- “Tralesinidase alfa (TA)”, 1 entry
Conditions, from the studies’ own filings
- Mucopolysaccharidosis III, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.